<DOC>
	<DOC>NCT02651740</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy as well as safety of rifaximin and fecal microbiota transplantation in the treatment of IBS-D.</brief_summary>
	<brief_title>Gut Microbiota Reconstruction for the Treatment of Diarrhea-predominant Irritable Bowel Syndrome</brief_title>
	<detailed_description>For IBS-D patients, rifaximin and fecal microbiota transplantation are given separately or together in order to evaluate the efficacy and safety of these two therapies compared with placebo.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Age between 18 and 65, no gender limitation; Had received a diagnosis of IBSD (as assessed according to the Rome III diagnosis criteria of IBS) and had undergone a colonoscopic examination within the previous 2 years with no organic lesions observed; Has current symptoms of IBSD: ①Abdominal pain (rated the average daily amount of abdominal pain as a score of more than 3 on a 010 point scoring system in a week (with 0 indicating no pain at all and 10 for a very great deal of pain)); ② Stool consistency (rated the consistency of their stools of Bristol types 6/7 (loose or watery) at least once a day and at least 2 days in a week); Can do followup at required time points and signed written informed consent before the study. Allergic to rifaximin; Taking alosetron, tegaserod, lubiprostone, warfarin, or antipsychotic, antispasmodic, antidiarrheal, probiotic, or narcotic drugs within the previous 1 month; Had infective diarrhea history or had taken antibiotics within the previous 14 days; Patients with a history of inflammatory bowel disease ; Previous abdominal surgery (other than cholecystectomy or appendectomy); Human immunodeficiency virus infection or other immunodeficiency conditions such as congenital immunodeficiency or currently taking immunesuppression drugs; Unstable diabetes, hypertension, thyroid disease, etc; Accompanied malignant tumor or severe heart/lung/renal/hepatic/brain/blood diseases; Accompanied severe neural/psychotic diseases such as epilepsy, depression, mania, schizophrenia, etc; Other conditions that doctor thought not suitable for the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Rifaximin</keyword>
	<keyword>Fecal microbiota transplantation</keyword>
</DOC>